This article by Dr Eleni Theocharidou et al. is published in Current Pharmaceutical Design, Volume 24, Issue 31, 2018 BENTHAM SCIENCE PUBLISHERS Statin treatment exhibits a beneficial effect in patients of cardiovascular diseases (CVD) and non–alcoholic fatty liver disease (NAFLD). Statins are common treatments for such conditions. The role of proprotein convertase subtilisin kexin type-9 (PCSK9) in the pathogenesis of NAFLD is summarized...